KR102861230B1 - Il-2r베타-선택적 효현제 및 지속 작용성 il-15 효현제의 조합 - Google Patents
Il-2r베타-선택적 효현제 및 지속 작용성 il-15 효현제의 조합Info
- Publication number
- KR102861230B1 KR102861230B1 KR1020187011922A KR20187011922A KR102861230B1 KR 102861230 B1 KR102861230 B1 KR 102861230B1 KR 1020187011922 A KR1020187011922 A KR 1020187011922A KR 20187011922 A KR20187011922 A KR 20187011922A KR 102861230 B1 KR102861230 B1 KR 102861230B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- acting
- long
- agonist
- daltons
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239207P | 2015-10-08 | 2015-10-08 | |
| US62/239,207 | 2015-10-08 | ||
| PCT/US2016/056088 WO2017062832A1 (en) | 2015-10-08 | 2016-10-07 | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180063184A KR20180063184A (ko) | 2018-06-11 |
| KR102861230B1 true KR102861230B1 (ko) | 2025-09-17 |
Family
ID=57249859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187011922A Active KR102861230B1 (ko) | 2015-10-08 | 2016-10-07 | Il-2r베타-선택적 효현제 및 지속 작용성 il-15 효현제의 조합 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12233104B2 (https=) |
| EP (1) | EP3359182B1 (https=) |
| JP (3) | JP7407511B2 (https=) |
| KR (1) | KR102861230B1 (https=) |
| CN (1) | CN108135978A (https=) |
| AU (1) | AU2016335860B2 (https=) |
| IL (1) | IL258456B (https=) |
| MA (1) | MA47290A (https=) |
| MX (1) | MX2018004296A (https=) |
| WO (1) | WO2017062832A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL270634B2 (en) * | 2017-05-15 | 2025-06-01 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
| US11248025B2 (en) | 2019-06-03 | 2022-02-15 | Medikine, Inc. | IL-2alpha receptor subunit binding compounds |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015125159A1 (en) * | 2014-02-21 | 2015-08-27 | Nektar Therapeutics (India) Pvt. Ltd. | Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401756A (en) | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| JP2524586B2 (ja) | 1985-06-26 | 1996-08-14 | シタス コーポレイション | ポリマ−接合を利用する医薬組成物用蛋白質の可溶化 |
| US4705848A (en) | 1986-06-02 | 1987-11-10 | International Minerals & Chemical Corp. | Isolation of bioactive, monomeric growth hormone |
| US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US6077519A (en) * | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
| AU1096595A (en) * | 1993-11-12 | 1995-05-29 | Gilead Sciences, Inc. | Thrombin mutants |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US6034072A (en) | 1997-02-10 | 2000-03-07 | Genemedicine, Inc. | IL-2 gene expression and delivery systems and uses |
| US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| JP4078032B2 (ja) | 1998-03-12 | 2008-04-23 | ネクター セラピューティックス エイエル，コーポレイション | 近位の反応性基を持つポリ（エチレングリコール）誘導体 |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| US6602498B2 (en) | 2000-02-22 | 2003-08-05 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| EP1349873B1 (en) | 2000-09-14 | 2009-04-01 | Beth Israel Deaconess Medical Center, Inc. | Modulation of il-2- and il-15-mediated t cell responses |
| CN1507357A (zh) | 2000-10-31 | 2004-06-23 | PRҩƷ����˾ | 提高生物活性分子传递的方法和组合物 |
| FR2826365B1 (fr) | 2001-06-20 | 2003-09-26 | Oreal | Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile |
| KR20050093856A (ko) | 2002-09-09 | 2005-09-23 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | 수용성 중합체 알카날 |
| GEP20084487B (en) | 2002-12-26 | 2008-09-25 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof |
| MXPA05007151A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Polimeros terminados en maleimida hidroliticamente estables. |
| KR101207247B1 (ko) | 2003-01-06 | 2012-12-03 | 넥타르 테라퓨틱스 | 티올-선택성 수용성 중합체 유도체 |
| PL1620118T3 (pl) | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
| EP2644206B1 (en) | 2003-05-23 | 2019-04-03 | Nektar Therapeutics | PEG derivatives containing two PEG chains |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| EP1670501A2 (en) | 2003-09-25 | 2006-06-21 | ZymoGenetics, Inc. | Methods of treating autoimmune diseases using il-21 |
| WO2005058366A2 (en) | 2003-12-10 | 2005-06-30 | Nektar Therapeutics Al, Corporation | Compositions comprising two different populations of polymer-active agent conjugates |
| TW200613552A (en) | 2004-08-11 | 2006-05-01 | Hoffmann La Roche | Mutant interleukin-15 polypeptides |
| JP2008515896A (ja) | 2004-10-05 | 2008-05-15 | オクスナー クリニック ファウンデーション | Ｉｌ−１５によるｂ細胞増殖の増強 |
| ATE367167T1 (de) | 2005-02-07 | 2007-08-15 | Novartis Vaccines & Diagnostic | Aufbereitung von aldesleukin zur pharmazeutischen verwendung |
| JP4560629B2 (ja) * | 2005-03-31 | 2010-10-13 | 国立大学法人 筑波大学 | 腫瘍壊死誘導療法の抗腫瘍効果増強剤 |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| KR101457223B1 (ko) | 2005-06-07 | 2014-11-04 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | ＴＮＦα를 억제하는 안정적이고 가용성인 항체 |
| HUE025208T2 (en) | 2005-06-16 | 2016-03-29 | Nektar Therapeutics | Conjugates with degradable binding and polymer reagents useful in the preparation of such conjugates |
| EP2364735A3 (en) | 2005-12-16 | 2012-04-11 | Nektar Therapeutics | Branched PEG conjugates of GLP-1 |
| CA2634167C (en) * | 2005-12-21 | 2015-06-16 | Sentoclone Ab | Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer |
| WO2007117685A2 (en) | 2006-04-07 | 2007-10-18 | Nektar Therapeutics Al, Corporation | Conjugates of an anti-tnf-alpha antibody |
| CN101104077A (zh) | 2006-07-12 | 2008-01-16 | 北京紫辰医药生物技术研究所 | 重组人白介素-2与聚乙二醇的偶合物 |
| JP5606738B2 (ja) | 2006-12-27 | 2014-10-15 | ウェルズ ファーゴ バンク ナショナル アソシエイション | 解離可能な連結を有する第ｉｘ因子部分−ポリマー共役体 |
| EP2114458B1 (en) | 2006-12-27 | 2014-02-26 | Nektar Therapeutics | Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage |
| EP2134181A4 (en) | 2007-02-28 | 2011-09-28 | Serina Therapeutics Inc | ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME |
| AU2009209565B2 (en) | 2008-02-01 | 2013-09-19 | Ascendis Pharma As | Prodrug comprising a self-cleavable linker |
| KR20090103209A (ko) | 2008-03-27 | 2009-10-01 | (주)한국비엠아이 | 사람 인터루킨-2 동종체 |
| WO2009135031A1 (en) * | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
| JP2011520447A (ja) | 2008-05-16 | 2011-07-21 | ネクター セラピューティックス | コリンエステラーゼ部分とポリマーとのコンジュゲート |
| WO2010014258A2 (en) | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| PL2431741T3 (pl) | 2008-10-21 | 2014-01-31 | Baxalta Inc | Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro) |
| TR201908836T4 (tr) | 2010-07-30 | 2019-07-22 | Baxalta GmbH | Oksim bağına yönelik nükleofilik katalizörler. |
| WO2012065086A1 (en) | 2010-11-12 | 2012-05-18 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
| WO2013020079A2 (en) * | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| MA39711A (fr) | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
-
2016
- 2016-10-07 WO PCT/US2016/056088 patent/WO2017062832A1/en not_active Ceased
- 2016-10-07 JP JP2018517898A patent/JP7407511B2/ja active Active
- 2016-10-07 EP EP16791713.7A patent/EP3359182B1/en active Active
- 2016-10-07 US US15/765,207 patent/US12233104B2/en active Active
- 2016-10-07 MA MA047290A patent/MA47290A/fr unknown
- 2016-10-07 AU AU2016335860A patent/AU2016335860B2/en active Active
- 2016-10-07 KR KR1020187011922A patent/KR102861230B1/ko active Active
- 2016-10-07 MX MX2018004296A patent/MX2018004296A/es unknown
- 2016-10-07 CN CN201680058497.XA patent/CN108135978A/zh active Pending
-
2018
- 2018-03-29 IL IL258456A patent/IL258456B/en unknown
-
2021
- 2021-02-04 JP JP2021016606A patent/JP2021066748A/ja not_active Withdrawn
-
2023
- 2023-05-24 JP JP2023085387A patent/JP2023099731A/ja not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015125159A1 (en) * | 2014-02-21 | 2015-08-27 | Nektar Therapeutics (India) Pvt. Ltd. | Il-2rbeta-selective agonists in combination with an anti-ctla-4 antibody or an an anti-pd-1 antibody |
Also Published As
| Publication number | Publication date |
|---|---|
| MA47290A (fr) | 2019-11-27 |
| KR20180063184A (ko) | 2018-06-11 |
| AU2016335860A1 (en) | 2018-04-12 |
| WO2017062832A1 (en) | 2017-04-13 |
| IL258456A (en) | 2018-06-28 |
| US20180296645A1 (en) | 2018-10-18 |
| JP7407511B2 (ja) | 2024-01-04 |
| HK1253347A1 (en) | 2019-06-14 |
| CA3000211A1 (en) | 2017-04-13 |
| MX2018004296A (es) | 2018-08-01 |
| JP2018530568A (ja) | 2018-10-18 |
| EP3359182B1 (en) | 2023-04-19 |
| CN108135978A (zh) | 2018-06-08 |
| US12233104B2 (en) | 2025-02-25 |
| AU2016335860B2 (en) | 2023-08-10 |
| IL258456B (en) | 2021-07-29 |
| JP2023099731A (ja) | 2023-07-13 |
| JP2021066748A (ja) | 2021-04-30 |
| EP3359182A1 (en) | 2018-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10786552B2 (en) | Il-2Rβ-selective agonists in combination with an anti-CTLA-4 antibody or an anti-PD-1 antibody | |
| US11318164B2 (en) | Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy | |
| KR20190105568A (ko) | 종양의 면역 요법적 치료 방법 | |
| JP2023099731A (ja) | ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 | |
| US20210154277A1 (en) | Immunotherapeutic combination for treating cancer | |
| CA3000211C (en) | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist | |
| HK1253347B (en) | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist | |
| HK40056474A (en) | Il-2rbeta-selective agonists in combination with an anti-pd-1 antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| F11 | Ip right granted following substantive examination |
Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 |
|
| U12 | Designation fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| Q13 | Ip right document published |
Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE) |